DiaMedica Therapeutics Inc (NAS:DMAC)
$ 2.825 -0.215 (-7.07%) Market Cap: 107.25 Mil Enterprise Value: 69.27 Mil PE Ratio: 0 PB Ratio: 2.32 GF Score: 37/100

Q1 2020 DiaMedica Therapeutics Inc Earnings Call Transcript

May 14, 2020 / 12:00PM GMT
Release Date Price: $4.5 (+17.19%)
Operator

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics conference call to discuss the top line results from DiaMedica's REMEDY Phase II clinical study in acute ischemic stroke and first quarter results. An audio recording of the webcast and a copy of the slide presentation will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investors section. I would now like to hand the call over to Rick Pauls, President and CEO. Please go ahead, sir.

Dietrich John Pauls
DiaMedica Therapeutics Inc. - President, CEO & Director

Thank you, Lisa, and good morning, everyone, and thank you for attending today's presentation. Before the company proceeds with our remarks, please note that the company will be making forward-looking statements on today's call. These statements are participant to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot